Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AKAP9
REST API REST API
Homo sapiens
AKAP9 is differentially expressed in 306 experiments: 146 organism parts: liver, trachea, ... (144 more);, 197 disease states: normal, cervical carcinoma, ... (195 more);, 82 cell types 427 cell lines 39 compound treatments and 79 other conditions.
Synonyms AKAP450, AKAP350, CG-NAP, KIAA0803, PRKA9, HYPERION, YOTIAO, MU-RMS-40.16A
Orthologs AKAP9 (Bos taurus)   CG13889 (Drosophila melanogaster)   AKAP9 (Danio rerio)   AKAP9 (Gallus gallus)   Akap9 (Mus musculus)   Q30A01_RAT (Rattus norvegicus)   ENSCING00000007060 (Ciona intestinalis)   akap9 (Xenopus laevis)   AKAP9 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, transport, protein binding, cytoskeleton, cytoplasm, pericentriolar material, mitotic cell cycle, Golgi apparatus, receptor binding, centrosome, synaptic transmission, G2/M transition of mitotic cell cycle, kinase activity, signal transduction
UniProt Accession Q99996, Q96KG3, Q6PJH3, Q8IW64, A4D1E4, E7EQ96, F5H3X5, F8WCY9
Gene-Disease Assocation LONG QT SYNDROME 11; LQT11
InterPro Term PACT_domain
Search EB-eye ENSG00000127914
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
U87
2
E-GEOD-20089, E-MEXP-903
H441
2
E-MTAB-62, E-GEOD-16194
AGS
2
E-MTAB-37, E-GEOD-15460
MOLT4
2
E-MTAB-62, E-MTAB-37
SKBR3
2
E-MEXP-440, E-MTAB-62
421 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, E-GEOD-13909, ... (44 experiments)

Factor Value U/D Experiments
centrocyte
2
E-GEOD-15271, E-TABM-702
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD4+ T cell
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
stromal cell
1
2
E-MEXP-2034, E-GEOD-10797, E-MEXP-1327
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MTAB-62, E-GEOD-5418, E-TABM-282, ... (54 experiments)

Factor Value U/D Experiments
cervical carcinoma
4
E-MTAB-62, E-GEOD-5823, E-MTAB-37, E-MEXP-1331
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
colon carcinoma
2
E-MTAB-62, E-MTAB-57
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
191 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
2
E-TABM-868, E-MEXP-1958, E-GEOD-3720
estradiol
1
E-GEOD-20081
phoshate buffered saline
1
E-GEOD-3720
Cxcl12
1
1
E-GEOD-7307
bacterial endotoxin
1
E-GEOD-3284
unknown
1
E-GEOD-7307
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Processing time: 0.31 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM